Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa
Garbayo-Salmons, Patricia (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Vilarrasa-Rull, Eva (Institut de Recerca Sant Pau)
Bassas-Vila, Julio (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Mora-Fernández, Veronica (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Fuertes, Irene (Hospital Clínic i Provincial de Barcelona)
Luque-Luna, Mar (Hospital Clínic i Provincial de Barcelona)
Fornons-Servent, Rosa (Hospital Universitari de Bellvitge)
Martin-Ezquerra, Gemma (Hospital del Mar (Barcelona, Catalunya))
Aguayo Ortiz, Rafael (Hospital Arnau de Vilanova (València))
Ceravalls, Joan (Hospital Universitari Sagrat Cor (Barcelona, Catalunya))
Mollet, Jordi (Hospital Universitari Vall d'Hebron)
Gómez Tomás, Álvaro (Hospital Universitari Vall d'Hebron)
Masferrer i Niubò, Emili (Hospital Universitari MútuaTerrassa)
Corral-Magaña, Oriol (Hospital Universitari MútuaTerrassa)
Matas-Nadal, Clara (Hospital de Santa Caterina (Salt, Girona))
del Estal, Jorge (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Fuertes Bailón, Dani (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Calvet, Joan (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Romaní, Jorge (Hospital General de Granollers)

Fecha:	2025
Resumen:	Background and Objectives: Survival analyses can provide valuable insights into effectiveness and safety as perceived by prescribers. Here, we aimed to evaluate adalimumab (ADA) survival and the interruption risk factors in a multicentre cohort of patients with hidradenitis suppurativa (HS). Moreover, we performed a subanalysis considering the periods before and after the onset of the COVID-19 pandemic. Methods: We conducted a retrospective study including 539 adult patients with HS who received ADA from 1 May 2015 to 31 December 2022. Overall drug survival was analysed using Kaplan-Meier survival curves and compared between the subgroups via stratified log-rank test. Possible predictors for overall drug survival and reasons for discontinuation were assessed using univariate and multivariate Cox regression. Results: Overall, 50. 1% were females with a mean age of 43. 5 ± 1 years and a mean BMI of 29. 5 ± 6. 7. At the start of ADA, 95. 29% were biologic-naïve and 24. 63% had undergone surgical treatment. During follow-up, 9. 46% of patients required dose escalation, while 39. 92% interrupted ADA. Concomitant therapy was used in 64. 89% of cases. A subanalyses comparing pre- and post-pandemic periods revealed a tendency to initiate ADA treatment at a younger age, among patient with higher BMI and at a lower HS stage after COVID-19 pandemic. Interestingly, ADA demonstrated extended survival compared to previous studies, with a median overall drug survival of 56. 2 months (95% CI 51. 2 to 80. 3). The primary causes for discontinuation were inefficacy (51. 69%), followed by adverse effects (21. 35%). Female sex, longer delay in HS diagnosis, higher baseline IHS4 score and concomitant spondyloarthritis were associated with poorer ADA survival or increased risk of discontinuation. Conclusions: ADA demonstrated prolonged survival (median 56. 2 months). While addition of antibiotics did not have a positive effect on survival rate, basal IHS4 proved useful in predicting ADA survival.
Derechos:	Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.
Lengua:	Anglès
Documento:	Article ; Versió acceptada per publicar
Materia:	Adalimumab ; Survival ; Discontinuation ; Hidradenitis suppurativa
Publicado en:	Journal of the European Academy of Dermatology and Venereology, Vol. 39 Núm. 1 (January 2025) , p. 221-229, ISSN 1468-3083

DOI: 10.1111/jdv.20044

Disponible a partir de: 2026-01-31 Postprint

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Instituto de Investigación e Innovación Parc Taulí (I3PT)
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos publicados